GlassScriptPhysician profile
Kaitlyn Tytka
NPI 1881161198
$10,688.95
in general payments reported to CMS, 2019-2025
67 companies · $2,632 in 2025
The $2,632 reported for 2025 was more than what 97% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $215 · 2022: $3,110 · 2023: $2,334 · 2024: $2,398 · 2025: $2,632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,197 · Education: $1,168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,196.67 |
| Education | $1,167.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,181.63 | 2022-2025 | Erleada, Akeega, Darzalex |
| Novartis Pharmaceuticals Corporation | $833.51 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $814.59 | 2021-2025 | Enhertu, Tagrisso, Calquence |
| Astellas Pharma US INC | $787.43 | 2022-2025 | Padcev, Xtandi |
| Merck Sharp & Dohme LLC | $504.10 | 2022-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $451.91 | 2022-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Aveo Pharmaceuticals, INC. | $448.60 | 2022-2025 | Fotivda |
| Pfizer INC. | $442.60 | 2022-2025 | |
| Celgene Corporation | $350.35 | 2021-2025 | Reblozyl, Opdivo |
| Abbvie INC. | $316.77 | 2022-2025 | |
| Glaxosmithkline, LLC. | $297.48 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Seagen INC. | $286.71 | 2022-2025 | Adcetris |
| Amgen INC. | $248.05 | 2021-2023 | Kyprolis, Xgeva, Vectibix |
| Eisai INC. | $226.53 | 2021-2025 | |
| Genzyme Corporation | $204.13 | 2021-2025 |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $203.83 | 2021-2024 | Verzenio, Jaypirca, Retevmo |
| Regeneron Healthcare Solutions, INC. | $196.67 | 2022-2024 | Libtayo |
| Rigel Pharmaceuticals, INC. | $184.05 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
| Gilead Sciences, INC. | $171.45 | 2022-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $163.36 | 2022-2023 | Opdivo |
| Medtronic, INC. | $160.94 | 2025 | Synchromedii |
| Array Biopharma INC | $157.77 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Incyte Corporation | $141.65 | 2021-2025 | Monjuvi, Pemazyre, Jakafi |
| Genentech USA, INC. | $134.26 | 2022-2025 | Tecentriq, Phesgo, Polivy |
| Pharmaessentia USA Corporation | $129.05 | 2022-2024 | Besremi |
| Janssen Scientific Affairs, LLC | $124.99 | 2023 | Erleada |
| Daiichi Sankyo INC. | $103.99 | 2022-2025 | Enhertu |
| Exelixis INC. | $94.53 | 2023-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $80.32 | 2021-2024 | |
| Beigene USA, INC. | $60.85 | 2021-2025 | Brukinsa |
| Karyopharm Therapeutics INC. | $54.60 | 2022-2024 | Xpovio |
| Foundation Medicine, INC. | $52.54 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $52.51 | 2024-2025 | Adstiladrin |
| Servier Pharmaceuticals LLC | $52.39 | 2023-2024 | |
| Emd Serono, INC. | $52.33 | 2023-2025 | Bavencio |
| Ipsen Biopharmaceuticals, INC | $52.22 | 2024-2025 | Onivyde |
| Tersera Therapeutics LLC | $51.90 | 2022-2025 | Zoladex |
| Pharmacyclics LLC, An Abbvie Company | $49.91 | 2022-2023 | Imbruvica |
| Pharmacosmos Therapeutics INC. | $49.02 | 2022-2023 | Monoferric |
| Dendreon Pharmaceuticals LLC | $42.22 | 2022-2023 | Provenge |
| Coherus Oncology, INC. | $42.16 | 2022-2024 | |
| Beone Medicines USA, INC. | $41.65 | 2025 | Tevimbra, Brukinsa |
| Puma Biotechnology, INC. | $37.09 | 2022-2023 | Nerlynx |
| Geron Corporation | $36.90 | 2024-2025 | Rytelo |
| Jazz Pharmaceuticals INC. | $35.15 | 2022 | |
| Epizyme, INC. | $34.50 | 2021-2022 | |
| Genmab U.S., INC. | $32.58 | 2024-2025 | Tivdak, Epkinly |
| Taiho Oncology, INC. | $32.17 | 2022-2024 | |
| Apellis Pharmaceuticals, INC. | $31.52 | 2025 | Empaveli |
| Cti Biopharma Corp. | $30.89 | 2022-2023 | Vonjo |
| Global Blood Therapeutics, INC. | $26.85 | 2022 | |
| Azurity Pharmaceuticals, INC. | $26.03 | 2025 | Danziten |
| Adaptive Biotechnologies Corporation | $24.95 | 2022 | |
| Adc Therapeutics America, INC. | $21.66 | 2024 | |
| Myriad Genetic Laboratories, INC. | $21.56 | 2025 | Myrisk |
| Janssen Pharmaceuticals, INC | $19.91 | 2022 | |
| Syndax Pharmaceuticals, INC. | $19.19 | 2025 | Revuforj |
| Alnylam Pharmaceuticals INC. | $17.90 | 2024 | Givlaari |
| Tg Therapeutics, INC. | $17.68 | 2022 | |
| Sandoz INC. | $17.32 | 2022 | |
| Accord Healthcare, INC. | $16.84 | 2025 | |
| Tempus Ai, INC | $16.69 | 2024 | |
| Mirati Therapeutics, INC. | $16.57 | 2024 | Krazati |
| Sumitomo Pharma America, INC. | $16.29 | 2025 | Orgovyx |
| Avyxa Pharma, LLC | $15.68 | 2024 | |
| Telix Pharmaceuticals | $13.93 | 2022 | |
| Novocure INC. | $13.55 | 2023 | Optune |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlyn Tytka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.